• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲状腺乳头状癌侧方淋巴结转移:系统评价和荟萃分析的患病率、危险因素和位置。

Lateral lymph node metastasis in papillary thyroid carcinoma: A systematic review and meta-analysis for prevalence, risk factors, and location.

机构信息

Department of Otorhinolaryngology-Head and Neck Surgery, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Republic of Korea.

Statistics and Data Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul, Republic of Korea.

出版信息

Int J Surg. 2018 Feb;50:94-103. doi: 10.1016/j.ijsu.2017.12.029. Epub 2018 Jan 9.

DOI:10.1016/j.ijsu.2017.12.029
PMID:29329789
Abstract

BACKGROUND

Lymph node metastasis (LNM) is frequent in papillary thyroid carcinoma (PTC) and is associated with a poor prognosis. Unlike central LNM (CLNM), there are few studies focusing on LLNM. We aimed to investigate the prevalence and the risk factors for LLNM, with its most prevalent sites.

METHODS

We performed a comprehensive literature search using the PubMed and EMBASE databases for relevant studies published prior to November 2016 that examined the risk factors for LLNM.

RESULTS

Twenty-three studies, including 18,741 patients, were included. The prevalence of LLNM was 20.9% in all patients. CLNM (pooled OR = 7.84, 95% CI = 6.13-10.02, p < .0001), extrathyroidal extension (pooled OR = 3.22, 95% CI = 2.21-4.70, p < .0001), tumor multifocality (pooled OR = 2.19, 95% CI = 1.67-2.89, p < .0001), male sex (pooled OR = 1.72, 95% CI = 1.50-1.98, p < .0001), upper pole location (pooled OR = 2.96, 95% CI = 1.93-4.53, p < .0001), tumor size ≥1.0 cm (pooled OR = 2.49, 95% CI = 1.71-3.61, p < .0001), lymphovascular invasion (pooled OR = 3.96, 95% CI = 2.61-6.03, p < .0001) and tumor bilaterality (pooled OR = 1.31, 95% CI = 1.12-1.53, p = .0006) were significantly associated with LLNM. Most frequently affected areas were levels III and IV.

CONCLUSIONS

The prevalence of LLNM was high although the prognostic impact is unknown. The significant risk factors for LLNM were not much different from known risk factors for CLNM.

摘要

背景

淋巴结转移(LNM)在甲状腺乳头状癌(PTC)中很常见,与预后不良有关。与中央区淋巴结转移(CLNM)不同,针对局灶性颈部淋巴结转移(LLNM)的研究较少。本研究旨在调查 LLNM 的流行率及其最常见的部位,并分析其相关的危险因素。

方法

我们使用 PubMed 和 EMBASE 数据库对截至 2016 年 11 月前发表的相关研究进行了全面的文献检索,以评估与 LLNM 相关的危险因素。

结果

共纳入 23 项研究,包含 18741 例患者。所有患者的 LLNM 流行率为 20.9%。CLNM(合并 OR=7.84,95%CI=6.13-10.02,p<0.0001)、甲状腺外侵犯(合并 OR=3.22,95%CI=2.21-4.70,p<0.0001)、肿瘤多灶性(合并 OR=2.19,95%CI=1.67-2.89,p<0.0001)、男性(合并 OR=1.72,95%CI=1.50-1.98,p<0.0001)、上极位置(合并 OR=2.96,95%CI=1.93-4.53,p<0.0001)、肿瘤直径≥1.0cm(合并 OR=2.49,95%CI=1.71-3.61,p<0.0001)、血管侵犯(合并 OR=3.96,95%CI=2.61-6.03,p<0.0001)和肿瘤双侧性(合并 OR=1.31,95%CI=1.12-1.53,p=0.0006)与 LLNM 显著相关。最常受累的区域是 III 区和 IV 区。

结论

LLNM 的流行率虽然较高,但预后影响尚不清楚。LLNM 的显著危险因素与 CLNM 的已知危险因素并无明显差异。

相似文献

1
Lateral lymph node metastasis in papillary thyroid carcinoma: A systematic review and meta-analysis for prevalence, risk factors, and location.甲状腺乳头状癌侧方淋巴结转移:系统评价和荟萃分析的患病率、危险因素和位置。
Int J Surg. 2018 Feb;50:94-103. doi: 10.1016/j.ijsu.2017.12.029. Epub 2018 Jan 9.
2
Evidence-based integration of clinicopathological factors with the risk of papillary thyroid carcinoma lateral cervical lymph node metastasis: systematic review and meta-analysis and subgroup study.基于证据的临床病理因素与甲状腺乳头状癌侧颈淋巴结转移风险的整合:系统评价、荟萃分析及亚组研究
Gland Surg. 2025 May 30;14(5):912-928. doi: 10.21037/gs-2025-60. Epub 2025 May 27.
3
Risk and Prognostic Factors for BRAF Mutations in Papillary Thyroid Carcinoma.甲状腺乳头状癌中 BRAF 突变的风险和预后因素。
Biomed Res Int. 2022 May 18;2022:9959649. doi: 10.1155/2022/9959649. eCollection 2022.
4
Predictive factors for central lymph node and lateral cervical lymph node metastases in papillary thyroid carcinoma.预测甲状腺乳头状癌中央区淋巴结和侧颈区淋巴结转移的因素。
Clin Transl Oncol. 2019 Nov;21(11):1482-1491. doi: 10.1007/s12094-019-02076-0. Epub 2019 Mar 16.
5
Pattern of and clinicopathologic risk factors for lateral lymph node metastases in papillary thyroid carcinoma patients with lateral cervical lymphadenopathy.伴有侧颈部淋巴结肿大的甲状腺乳头状癌患者侧方淋巴结转移的模式及临床病理危险因素
Medicine (Baltimore). 2018 Sep;97(36):e12263. doi: 10.1097/MD.0000000000012263.
6
Lateral lymph node metastasis in papillary thyroid microcarcinoma: a study of 5241 follow-up patients.甲状腺微小乳头状癌侧颈部淋巴结转移:5241 例随访患者研究。
Endocrine. 2024 Feb;83(2):414-421. doi: 10.1007/s12020-023-03486-5. Epub 2023 Aug 18.
7
Clinical risk factors for central lymph node metastasis in papillary thyroid carcinoma: a systematic review and meta-analysis.甲状腺乳头状癌中央淋巴结转移的临床危险因素:一项系统评价和Meta分析
Clin Endocrinol (Oxf). 2015 Jul;83(1):124-32. doi: 10.1111/cen.12583. Epub 2014 Sep 22.
8
Pretreatment level of circulating tumor cells is associated with lymph node metastasis in papillary thyroid carcinoma patients with ≤ 55 years old.55岁及以下乳头状甲状腺癌患者的循环肿瘤细胞预处理水平与淋巴结转移相关。
World J Surg Oncol. 2025 Jan 29;23(1):29. doi: 10.1186/s12957-025-03670-z.
9
Significance of multifocality in papillary thyroid carcinoma.多灶性在甲状腺乳头状癌中的意义。
Eur J Surg Oncol. 2020 Oct;46(10 Pt A):1820-1828. doi: 10.1016/j.ejso.2020.06.015. Epub 2020 Jun 19.
10
Risk factor analysis for predicting cervical lymph node metastasis in papillary thyroid carcinoma: a study of 966 patients.分析预测甲状腺乳头状癌颈淋巴结转移的风险因素:966 例患者研究。
BMC Cancer. 2019 Jun 25;19(1):622. doi: 10.1186/s12885-019-5835-6.

引用本文的文献

1
Preoperative identification of the risk factors of cervical lymph node metastasis in medullary thyroid carcinoma.甲状腺髓样癌颈淋巴结转移危险因素的术前识别
Front Endocrinol (Lausanne). 2025 Aug 21;16:1576955. doi: 10.3389/fendo.2025.1576955. eCollection 2025.
2
Is it possible to rule out level II and level VB dissection in patients with metastatic papillary thyroid cancer?对于转移性乳头状甲状腺癌患者,是否有可能排除II级和VB级淋巴结清扫?
Front Endocrinol (Lausanne). 2025 Aug 11;16:1520539. doi: 10.3389/fendo.2025.1520539. eCollection 2025.
3
A Model Predicting Occult Metastases in Lateral Lymph Nodes in pN1a Stage Papillary Thyroid Cancer.
预测pN1a期乳头状甲状腺癌侧方淋巴结隐匿性转移的模型
Int J Gen Med. 2025 Aug 6;18:4279-4290. doi: 10.2147/IJGM.S528876. eCollection 2025.
4
Lobectomy vs total thyroidectomy for unilateral papillary thyroid carcinoma with ipsilateral cervical lymph node metastasis.肺叶切除术与全甲状腺切除术治疗单侧甲状腺乳头状癌伴同侧颈部淋巴结转移的对比
Front Endocrinol (Lausanne). 2025 Jul 24;16:1564752. doi: 10.3389/fendo.2025.1564752. eCollection 2025.
5
A predictive model using platelets and neutrophil-to-lymphocyte ratio for the number of lymph node metastases in papillary thyroid carcinoma: a retrospective analysis.一项使用血小板和中性粒细胞与淋巴细胞比值预测甲状腺乳头状癌淋巴结转移数量的模型:一项回顾性分析
Gland Surg. 2025 Jul 31;14(7):1283-1294. doi: 10.21037/gs-2025-119. Epub 2025 Jul 28.
6
Precision of predictive nomograms for lymph node metastasis of thyroid cancer from Chinese real-world study: a systematic review and meta-analysis.来自中国真实世界研究的甲状腺癌淋巴结转移预测列线图的准确性:一项系统评价和荟萃分析。
Front Endocrinol (Lausanne). 2025 Jul 9;16:1617563. doi: 10.3389/fendo.2025.1617563. eCollection 2025.
7
Predicting the Unexpected: Clinicopathological Insights into Skip Metastasis in Papillary Thyroid Carcinoma.预测意外情况:甲状腺乳头状癌跳跃转移的临床病理见解
J Clin Med. 2025 Jun 15;14(12):4255. doi: 10.3390/jcm14124255.
8
Evidence-based integration of clinicopathological factors with the risk of papillary thyroid carcinoma lateral cervical lymph node metastasis: systematic review and meta-analysis and subgroup study.基于证据的临床病理因素与甲状腺乳头状癌侧颈淋巴结转移风险的整合:系统评价、荟萃分析及亚组研究
Gland Surg. 2025 May 30;14(5):912-928. doi: 10.21037/gs-2025-60. Epub 2025 May 27.
9
Cutaneous manifestation of metastatic papillary thyroid carcinoma.转移性甲状腺乳头状癌的皮肤表现。
JAAD Case Rep. 2025 Apr 11;60:129-131. doi: 10.1016/j.jdcr.2025.03.023. eCollection 2025 Jun.
10
Multifactorial risk stratification for central lymph node metastasis in papillary thyroid carcinoma: a predictive model integrating clinical and tumor characteristics.甲状腺乳头状癌中央淋巴结转移的多因素风险分层:整合临床和肿瘤特征的预测模型
Front Oncol. 2025 May 21;15:1586307. doi: 10.3389/fonc.2025.1586307. eCollection 2025.